Fusion Pharmaceuticals and Triumf Announce Expanded R&D Collaboration for Actinium Supply Production
August 12, 2021 at 04:05 pm EDT
Fusion Pharmaceuticals Inc. announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have rights, including preferred access and pricing, to the resulting alpha-emitting medical isotope.